Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + apatinib in HCC after hepatectomy
NCT03722875Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Relapse-Free Survival at 1 year and Overall Survival at 3 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03722875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722875.